达沙替尼衍生物示踪剂用于肿瘤激酶靶向PET的首个人体试验
这项前瞻性首个人体试验纳入5例乳腺癌、肾细胞癌或白血病患者,注射18F-SKI-249380后行全身PET/CT,评估生物分布、剂量学和肿瘤摄取。结果显示注射后无不良事件,27个肿瘤病灶中位SUVpeak为1.4,肿瘤/血比值1.6,有效剂量0.0258 mSv/MBq。
要点
- 5例恶性肿瘤患者注射18F-SKI后无不良事件,示踪剂主要经肝胆途径清除。
- 27个肿瘤病灶90分钟中位SUVpeak为1.4(范围0.7-2.3),肿瘤/血比值1.6(范围0.8-2.5)。
- 有效剂量为0.0258 mSv/MBq(SD,0.0034 mSv/MBq),最高吸收剂量在右结肠和小肠。
核心结论
- 18F-SKI-249380在肿瘤中显示显著摄取,注射剂量低但图像对比清晰,且血液清除迅速。
研究设计与样本
- 前瞻性首个人体试验,纳入5例既往诊断为乳腺癌、肾细胞癌或白血病的患者。
- 注射18F-SKI-249380(平均241.24±116.36 MBq)后90分钟行全身PET/CT,其中2例行上腹部30分钟动态扫描,3例行注射后三次10分钟全身PET/CT,3例在180分钟行延迟全身PET/CT。
主要发现
- 注射后无不良事件;共分析27个肿瘤病灶,90分钟中位SUVpeak为1.4(范围0.7-2.3),肿瘤/血比值为1.6(范围0.8-2.5)。
- 4个参考病灶的瘤内药物浓度范围为0.03至0.07 nM,所有参考病灶在注射后30至90分钟之间示踪剂蓄积恒定。
- 血液放射性检测显示血液半衰期1.31±0.81分钟、血浆半衰期1.07±0.66分钟(n=4),随后或呈延长的终末相(血液285±148.49分钟、血浆240±84.85分钟,n=2)或小幅上升至平台(n=2)。
- 18F-SKI像达沙替尼一样在给药后发生广泛代谢,放射性主要经肝胆途径清除。
- 正常组织中最高吸收剂量估计(mGy/MBq)为右结肠0.167±0.04和小肠0.153±0.03,有效剂量为0.0258 mSv/MBq(SD,0.0034 mSv/MBq)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We developed a first-of-kind dasatinib-derivative imaging agent, 18F-SKI-249380 (18F-SKI), and validated its use for noninvasive in vivo tyrosine kinase-targeted tumor detection in preclinical models. In this study, we assessed the feasibility of using 18F-SKI for PET imaging in patients with malignancies. Methods: Five patients with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-body PET/CT imaging 90 min after injection of 18F-SKI (mean, 241.24 ± 116.36 MBq) as part of a prospective study. In addition, patients underwent either a 30-min dynamic scan of the upper abdomen including, at least partly, cardiac left ventricle, liver, spleen, and kidney (n = 2) or three 10-min whole-body PET/CT scans (n = 3) immediately after injection and blood-based radioactivity measurements to determine the time course of tracer distribution and facilitate radiation dose estimates. A subset of 3 patients had a delayed whole-body PET/CT scan at 180 min. Biodistribution, dosimetry, and tumor uptake were quantified. Absorbed doses were calculated using OLINDA/EXM 1.0. Results: No adverse events occurred after injection of 18F-SKI. In total, 27 tumor lesions were analyzed, with a median SUVpeak of 1.4 (range, 0.7-2.3) and tumor-to-blood ratios of 1.6 (range, 0.8-2.5) at 90 min after injection. The intratumoral drug concentrations calculated for 4 reference lesions ranged from 0.03 to 0.07 nM. In all reference lesions, constant tracer accumulation was observed between 30 and 90 min after injection. A blood radioassay indicated that radiotracer clearance from blood and plasma was initially rapid (blood half-time, 1.31 ± 0.81 min; plasma, 1.07 ± 0.66 min; n = 4), followed variably by either a prolonged terminal phase (blood half-time, 285 ± 148.49 min; plasma, 240 ± 84.85 min; n = 2) or a small rise to a plateau (n = 2). Like dasatinib, 18F-SKI underwent extensive metabolism after administration, as evidenced by metabolite analysis. Radioactivity was predominantly cleared via the hepatobiliary route. The highest absorbed dose estimates (mGy/MBq) in normal tissues were to the right colon (0.167 ± 0.04) and small intestine (0.153 ± 0.03). The effective dose was 0.0258 mSv/MBq (SD, 0.0034 mSv/MBq). Conclusion:18F-SKI demonstrated significant tumor uptake, distinct image contrast despite low injected doses, and rapid clearance from blood.
引用
- Krebs S, Veach DR, Carter LM, et al. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. J Nucl Med. 2020. PMID: 32169913. doi:10.2967/jnumed.119.234864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。